{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T10:00:34Z","timestamp":1753437634826},"reference-count":52,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2016,5,24]],"date-time":"2016-05-24T00:00:00Z","timestamp":1464048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:p>Tyrosine kinase inhibitor (TKI) therapy yields sustained cytogenetic remissions in most patients with chronic\u2010phase chronic myeloid leukemia (CML). Peripheral blood quantitative reverse transcription polymerase chain reaction (qRT\u2010PCR) monitoring of the chimeric <jats:italic>BCR\u2010ABL1<\/jats:italic> mRNA transcript levels is a very sensitive method to measure disease burden in patients with cytogenetic remission. qRT\u2010PCR allows identification of patients (1) at high risk of progression early (3\u20136 months) after treatment initiation, (2) with no response to TKI therapy, (3) with undetectable disease who could be eligible for TKI discontinuation trials. Molecular monitoring is a minimally invasive method to optimize treatment and outcomes in CML. Am. J. Hematol. 91:742\u2013746, 2016. \u00a9 2016 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.24381","type":"journal-article","created":{"date-parts":[[2016,4,10]],"date-time":"2016-04-10T12:53:02Z","timestamp":1460292782000},"page":"742-746","source":"Crossref","is-referenced-by-count":8,"title":["Monitoring disease burden in chronic myeloid leukemia: Past, present, and future"],"prefix":"10.1002","volume":"91","author":[{"given":"Daniel","family":"Egan","sequence":"first","affiliation":[{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center Seattle Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerald","family":"Radich","sequence":"additional","affiliation":[{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center Seattle Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,5,24]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.07.001"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.12.4064.bloodjournal84124064"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199403243301204"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92596-1"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.38"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-410688"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-510396"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-511592"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/1947601912462126"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20922"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1516"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-383000"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390120"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306494"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2619"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348110"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483750"},{"key":"e_1_2_7_23_1","first-page":"513","article-title":"Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: Transplant activity, long\u2010term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"91","author":"Gratwohl A","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21032"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.4065\/81.7.973"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-204693"},{"key":"e_1_2_7_27_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1385\/1-59259-363-1:009","volume-title":"Cancer cytogenetics: Methods and protocols","author":"Swansbury J","year":"2003"},{"key":"e_1_2_7_28_1","unstructured":"National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. V1.2016. Available at:http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf. Accessed March 28 2016."},{"key":"e_1_2_7_29_1","first-page":"994","article-title":"Fluorescence in situ hybridization analysis of minimal residual disease and the relevance of the der(9) deletion in imatinib\u2010treated patients with chronic myeloid leukemia","volume":"91","author":"Calabrese G","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_7_30_1","first-page":"2535","article-title":"Interphase FISH for follow\u2010up of Philadelphia chromosome\u2010positive chronic myeloid leukemia treatment","volume":"24","author":"Douet\u2010Guilbert N","year":"2004","journal-title":"Anticancer Res"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403077"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737159.2013.835573"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030513"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3547"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3530"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25123"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2005.01.008"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1134"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-309807"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2014.20.10.1006"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-487728"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2198"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-451"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1208715109"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-0092"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.741577"},{"key":"e_1_2_7_49_1","first-page":"124","article-title":"BCR\u2010ABL testing frequency lower than NCCN recommendations in lab network review of CML patients","author":"Smyth C","year":"2014","journal-title":"Blood"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2014.001099"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.555569"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2014.221366"},{"key":"e_1_2_7_53_1","first-page":"501","article-title":"Laboratory tools for diagnosis and monitoring response in patients with chronic myeloid leukemia","volume":"14","author":"Tohami T","year":"2012","journal-title":"Isr Med Assoc J"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24381","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T20:57:47Z","timestamp":1695502667000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,24]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.1002\/ajh.24381"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24381","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,24]]}}}